SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant volatility and a steep sell-off after disclosing that Marvell canceled its purchase orders due to a confidentiality breach caused by public remarks from management. The community is sharply divided, with many retail investors expressing frustration over the lack of transparency while others view the dip as an opportunity to accumulate shares, betting on the long-term viability of the company's photonics technology.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened volatility as the community debates its long-term AI strategy, driven by reports that OpenAI may partner with the company to develop custom smartphone processors. Investors remain divided, with some betting on a reversal and AI-driven growth, while others express frustration over recent price fluctuations and persistent short-term bearish sentiment.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is surging toward record highs, driven by explosive AI-related demand for its NAND memory and intense speculation surrounding a potential stock split ahead of its upcoming earnings report. The community remains deeply divided, with bulls pointing to robust fundamentals and a 'memory supercycle,' while bears remain skeptical of the stock's parabolic valuation and fear an imminent correction.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail attention driven by high volatility and heavy short interest, leading traders to discuss the potential for a short squeeze despite skepticism surrounding the company's fundamentals and recent price action. The community remains divided, with some actively trading the sharp price swings while others warn of the risks associated with the stock's unpredictable performance.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following a positive readout for its late-stage HAE study, which bolstered the bull case for its in vivo CRISPR platform despite intense scrutiny from shorts. Investors are heavily focused on the implications for future drug adoption, institutional positioning, and the potential for a significant short squeeze as the company moves toward regulatory milestones.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened selling pressure and negative sentiment due to concerns over regulatory uncertainty, particularly regarding the impact of proposed legislation and the competitive landscape of prediction markets. Community discourse remains deeply divided, with bearish investors citing management's consistent share selling and weak stock performance, while long-term bulls point to potential expansion opportunities and the belief that the stock is currently undervalued.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending as investors weigh the significant valuation disconnect between its recent acne trial success and its current market capitalization, while speculation intensifies regarding potential acquisition interest from larger players in the MASH space. Community sentiment remains split between long-term confidence in the drug's multi-indication pipeline and short-term frustration over price volatility and the lack of immediate monotherapy funding for its MASH program.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as the company accelerates its New York flight campaign and secures key regulatory approvals for operations, fueling optimism among investors tracking its progress toward commercial launch. While community sentiment is heavily polarized between long-term supporters focused on these engineering milestones and skeptics pointing to high cash burn and technical volatility, traders are actively monitoring the stock's significant options activity and price action around key resistance levels.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing high volatility as investors weigh the potential for government contract awards against frustration with management's communication regarding timelines and guidance. The community is focused on the company's drone integration with U.S. military platforms and remains split between optimism for future revenue growth and skepticism over the timing of major defense milestones.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is experiencing significant community momentum as investors anticipate the official U.S. launch of its predictive betting platform, a move bolstered by recent strategic marketing partnerships. Market participants are actively discussing a potential squeeze driven by a tight float, high short interest, and the stock's positioning as a pure-play opportunity in the rapidly expanding predictive betting sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The main goal of the study is to evaluate safety, feasibility, and tolerability, track tumor response, disease progression, and survival outcomes</li><li>The biotech firm also marked the debut of its Alpha DaRT therapy for pancreatic cancer in Europe.</li></ul>Shares of Alpha Tau Medical (DRTS) drew strong retail attention on Friday, rising nearly 4% in pre-market trading after the company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.On Thursday, the U.S. Food and Drug Administration (FDA) cleared an Investigational Device Exemption (IDE) supplement to expand its pancreatic cancer study, known as the IMPACT trial, which is testing its Alpha DaRT therapy alongside chemotherapy.The update allows the company to enroll 10 additional patients receiving the chemotherapy combination Gemcitabine and Abraxane, split evenly between locally advanced and metastatic pancreatic cancer cases. This expansion takes the total enrollment to 40 patients.The IMPACT study is a multi-center trial across the U.S., Canada, and Israel, focusing on patients with recently diagnosed, inoperable pancreatic adenocarcinoma. The main goal of the study is to evaluate safety, feasibility, and tolerability, while also tracking tumor response, disease progression, survival outcomes, and patient-reported pain relief.<h2 class="st-heading-2">Retail Bullish On Trial Expansion</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DRTS">DRTS</a> on Stocktwits turned ‘bullish’ from ‘neutral,’ a day earlier, amid ‘high’ message volumes. Chatter on the platform was up by 200% over the past 24 hours.One user said the trial expansion wouldn’t have taken place if the “safety profile wasn’t looking solid.”<stembedurl>https://stocktwits.com/mattstk2000/message/651253093</stembedurl>Another user was bullish on the company’s prospects for treating pancreatic cancer.<stembedurl>https://stocktwits.com/Pristine_Hurry/message/651252964</stembedurl><h2 class="st-heading-2">Treats First Patient In Europe</h2>Alpha Tau Medical also said it treated the first patient in its ACAPELLA trial, marking the debut of its Alpha DaRT therapy for pancreatic cancer in Europe. The study is testing Alpha DaRT alongside Capecitabine in patients with inoperable, locally advanced disease who have already completed standard chemotherapy.Management said the trial targets a major care gap, as there is currently no standard follow-up treatment for such patients. Pancreatic cancer remains highly lethal, with about 30% of Europe’s 140,000 annual cases diagnosed at this stage.“Over forty thousand Europeans each year are diagnosed with inoperable locally advanced pancreatic cancer, and even if there are some patients who have managed to complete first-line chemotherapy, there remains no established next step, no standard treatment path, and an inevitable progression for the great majority. That is the great unmet need ACAPELLA was designed to address,” CEO Uzi Sofer said.DRTS shares have surged more than 57% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ogn-stock-rising-in-pre-market-today/cZBWU3fReTp">Why Is OGN Stock Rising In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

DRTS Stock Pops Pre-Market: Retail Hype Soars On Cancer Trial Expansion

The company announced key progress in its pancreatic cancer program, including regulatory approval to expand its ongoing trial by enrolling an additional 10 patients.

DRTS Is Back On Retail Radar: These Two Catalysts Are Driving The Rally

Equity

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat...

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 771,223...

Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2%  - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2% - Still a Buy...

Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F...

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients with newly diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The ReSTART study is to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, a common form of skin cancer.</li><li>Patient enrollment for both trials is expected to be completed by the end of the first quarter of 2026.</li></ul>Alpha Tau Medical (DRTS) drew strong retail attention on Monday as the oncology therapeutics firm approaches a key catalyst, with markets awaiting crucial patient enrolment data in pancreatic cancer and cutaneous squamous cell carcinoma (cSCC) trials.<a href="https://stocktwits.com/symbol/DRTS">DRTS shares</a> were down 4% in pre-market trading at the time of writing.<h2 class="st-heading-2">IMPACT Study For Pancreatic Cancer</h2>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on those with newly diagnosed, inoperable pancreatic adenocarcinoma. Patient enrollment is expected to be completed by the end of the first quarter of 2026.Participants will continue standard chemotherapy while receiving the company’s Alpha DaRT, a targeted radiation therapy delivered directly into tumors using ultrasound-guided endoscopy.The study aims to evaluate the safety, feasibility, and effectiveness of the treatment, while also tracking tumor response and survival outcomes. Researchers will additionally assess whether some patients with locally advanced disease become eligible for surgery after treatment, a key potential benefit of the therapy, the company said.<h2 class="st-heading-2">ReSTART Trial Targets Skin Cancer Opportunity</h2>Alpha Tau is currently running its multi-center ReSTART study to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. Patient enrollment is expected to be completed in the first quarter of 2026.The trial supports the use of Alpha DaRT, particularly for patients who are not eligible for surgery or standard radiation.The company has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration for this indication, as well as for recurrent glioblastoma multiforme, a type of brain tumor, and oral cavity cancers.This designation reflects the regulator’s view that the therapy could offer significant advantages over existing treatments and allows for an accelerated review and development pathway. It is also part of the FDA’s Total Product Life Cycle Advisory Program.<h2 class="st-heading-2">DRTS Stock: Retail Sentiment Signals High Expectations&nbsp;</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/DRTS_jpg_933216b5d9.webp" alt="DRTS.jpg">Chatter was largely bullish, with one user stating that the company’s current market value could look very low in hindsight if there are further positive updates from the ReSTART trial.<stembedurl>https://stocktwits.com/Joshsim123/message/648904774</stembedurl>Another user said the stock’s current value feels like a “massive mispricing.”<stembedurl>https://stocktwits.com/Jessypenny/message/648902299</stembedurl>Year-to-date, the stock has gained nearly 38%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-gains-california-pipeline-restart-sales/cZERVWqRIZt">Sable Offshore Begins Oil Sales From Highly Scrutinized California Pipeline – SOC Stock Gains 3% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

DRTS Stock Is Back On Retail Radar Ahead Of High-Stakes Cancer Trial Updates

The market is awaiting the company’s patient enrolment data from pancreatic cancer and cutaneous squamous cell carcinoma trials, a key factor in advancing the studies.

Why Alpha Tau Is Back On Traders’ Radar? 

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of "Hold" by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research...

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up   - Here's Why

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's What Happened...

Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as real and meaningful activity over the...

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

Earnings

Fed / Macro data

Headlines / Geopolitics

Other (drop a comment)

What will be the main driver of the market this week?

Stocktwits

Stocktwits Polls

ALPHA TAU MEDICAL LTD

Investors are rapidly building positions ahead of the May 2nd Digestive Disease Week presentation featuring critical pancreatic cancer data.

The recent FDA-approved expansion of the IMPACT study and the first European patient treatment in the ACAPELLA trial signify massive clinical progress.

Traders are betting on a major breakout, eyeing a swift move into double-digit price territory fueled by high-conviction momentum.

Current Price	$8.00
Prev Close	$8.09
Open	$8.10
Dividend Yield	0.00%
50-Day Moving Average	$7.34
Beta	0.76
Avg. Volume	246,701.31
PE Ratio	-15.32

52-Week High	$8.60
52-Week Low	$2.50
Market Capitalization	$712M
EPS (Annual)	-$0.529
Price to Book	9.23
Revenue Per Employee	$0.00

DRTS
ALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRTS News

DRTSALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRTS News

DRTS
ALPHA TAU MEDICAL LTD